Meeting
2016 ASCO Annual Meeting
Increased FoxP3 and PD-L1 in non-pCR tissue from early stage HER2 positive breast cancer patients treated with trastuzumab-pertuzumab based regimens.
Authors
Jeremy Meyer Force
Duke University Medical Center, Department of Hematology/Oncology, Durham, NC
Jeremy Meyer Force , Lynn Jackson Howie , Sara Abbott , Rex C. Bentley , Paul K. Marcom , Gretchen Genevieve Kimmick , Kelly E. Westbrook , Michelle Parks , Donna L. Topping , Gloria Broadwater , Kimberly L. Blackwell , Smita K Nair
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 34, 2016 (suppl; abstr 602)
DOI
10.1200/JCO.2016.34.15_suppl.602
Abstract #
602
Poster Bd #
90
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.
First Author: Giampaolo Bianchini
Poster
2016 ASCO Annual Meeting
Tolerability and effectiveness of pertuzumab-containing neoadjuvant (NA) regimens vs. AC-TH for HER2-positive (+) localized breast cancer (BC).
First Author: Laura Spring
Poster
2016 ASCO Annual Meeting
Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
First Author: Sinead Toomey
Poster
2015 ASCO Annual Meeting
A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).
First Author: Andreas Schneeweiss